StockWatch
·

Trualt Bioenergy Ltd Q1 FY27 Results

TRUALTQ1 FY27 Results
Filing
Result:Very Good· Market: UpTurnaroundMargin expansionBroad based

Outlook: Optimistic · Guidance: Maintained

MetricValueQ4 FY26Q1 FY26
Revenue626.88 Cr5.3%106.3%
Total Income641.41 Cr2.3%96.4%
Expenditure562.96 Cr3.6%75.5%
PBT78.45 Cr6.3%1252.6%
Net Profit59.27 Cr2.8%1154.4%
OPM21.18%1.24pp7.51pp
NPM9.24%0.48pp7.79pp
EPS6.674.6%895.5%
View full financials

Ethanol-led revenue more than doubled and operating margin expanded ~750bps YoY (13.7%→21.2%), with the prior-year quarter's near-breakeven print reflecting genuine tender-allocation disruption rather than a manufactured base, making this a standout core-business recovery for the sector.

TRUALT BIOENERGY · Q1 FY27 · THE VERDICT

Dual-Feed Payoff Is Real, but Q2 Will Strip Away the Windfall

Headline numbers soar (106% revenue, 1154% profit YoY), but Q1 saw PAT fall 2.8% QoQ despite higher volumes. The maize inventory benefit inflates margins by ₹9–10 per liter—a non-recurring tailwind that ends next quarter.

17 Aug 2026 · 6 min read
Reported PAT

₹59.3 Cr

+1,154% YoY, -2.8% QoQ

Inventory benefit

~₹9–10/liter

Maize ₹18-22 vs. spot ₹25.50

Adjusted EBITDA/liter

~₹10–12

vs. ₹15–16 on lock-in

The tension: Headline growth masks margin compression

TruAlt reported a blowout: ₹626.9 Cr revenue (+106% YoY), ₹59.3 Cr PAT (+1,154% YoY). The day-1 market reaction was +2.62% delivery. On a 52-week chart, the pop held—day 5 still up +4.19%. But the call reveals the real story. Despite Q1 revenues rising 5.3% QoQ, PAT fell 2.8%. That gap—growth without leverage—tells you margin pressure is already here.

The culprit is inventory. TruAlt booked maize at ₹18–₹22 per kg when it was cheaper. That stock is now valued against a spot price of ₹25.50/kg—a ₹9–₹10 per liter margin benefit that is non-recurring. Once the dual-feed plants cycle through that inventory (expected Q2), normalized maize cost yields only ₹6–₹7 per liter margin, versus the ₹15–₹16 the quarter is banking on. Employee cost additions (180 CBG hires) and a ₹11 Cr finance drag absorbed the volume uplift.

Management's key claims vs. what holds up

Revenue close to ₹630 Cr, ethanol 8.5 Cr liters produced

₹626.9 Cr revenue, 8.5 Cr liter sales guidance matched

Supported

44 Cr liters orders on hand for FY27

44 Cr liters confirmed; 55 Cr capacity target implied 80% conversion, not a miss

Supported (but partial guidance)

Grain-based feedstock 6% margin better than sugar

Confirmed: grain ₹314 Cr vs. sugar ₹277 Cr on similar volume; 50:50 blend this Q

Supported

CBG 40–50% PAT margin at 78% utilization

CBG ₹11.2 Cr revenue, ₹5.1 Cr PBT = 45.5% margin; 1x maintenance cost cited

Supported

15 Cr liter court case implementation imminent

MD: 'still stands open, making all efforts' but no timeline disclosed

Unresolved—not in base 44 Cr guidance

What changed on this call

  • Dual-feed transition complete: 3 of 5 plants on grain blend; 6% margin lift realized

  • CBG capex accelerated: 132 TPD new capacity by Q4 FY27 (vs. FY28 prior), ₹760 Cr gross, 70:30 debt

  • Maize cost trajectory deteriorated: ₹25.50/kg spot vs. ₹22–24 normalized; Q2 headwind ₹9–10/liter

  • Fuel retail expansion stalled: 76 outlets identified, 7 live, 4 in pipeline; deferred due to Middle East crude volatility

  • Guidance maintained (55 Cr liters ethanol, CBG, SAF capex), not raised; implicit 44 Cr order base vs. capacity target

The bull-bear ledger

  • Dual-feed economics proven: grain margin 6% better than sugar; yield 450 vs. 317; co-product DDGS ₹47 Cr upside

  • CBG pilot validated: 45.5% PAT margin, 78% utilization; JV capex accelerated to Q4 revenue start

  • 44 Cr liters orders provide visibility; OMC + private + ENA channels diversified

  • Reported PAT soared (+1,154% YoY) but Q1 QoQ fell 2.8% despite 5.3% revenue growth—no leverage materializing

  • Inventory margin benefit ₹9–10/liter non-recurring; normalized maize ₹6–7/liter hits Q2

  • Only 44 Cr liters (80% capacity) vs. 55 Cr target; 15 Cr liter court case unresolved—tender allocation risk

  • Finance cost ₹44 Cr annualized (₹11 Cr this Q) = 7% of revenue; de-leverage plan pending, not disclosed

  • CBG policy in flux: MDA (fertilizer subsidy) dependence for FOM monetization; Sampoorna program rollout uncertain

  • SAF adoption uncertain: ₹2,000 Cr capex, FY29 revenue, ₹180–200/liter price = 1.8x ATF; airline cost sensitivity high

Risks, ranked by how much they should concern a holder

Key risks to earnings and capital deployment

Inventory margin windfall fades Q2

High

Maize ₹18–22 lock-in realizing ₹15–16/liter margin; spot ₹25.50 yields ₹6–7/liter. Q2 procurement headwind ₹9–10/liter. Strip away the benefit and adjusted EBITDA margin falls to 16–18% from Q1's 23.5%.

Tender allocation fairness (44 Cr vs. 55 Cr capacity)

High

Only 80% utilization on filed capacity. MD flagged 'unfair means' in prior allocation. Sept–Oct new ethanol bidding cycle critical. If 44 Cr holds, FY27 revenue tops out ~₹3,000 Cr (vs. ₹3,700 Cr at full capacity).

Maize cost volatility

High

At ₹22–24/kg (normalized), margins ₹10–12/liter; locked-in benefit ₹9–10/liter masks Q2 pressure. Spot ₹25.50 already compresses to ₹6–7/liter. Policy change or global supply shock could extend the pain.

Finance cost burden

Medium-High

₹44 Cr annualized (₹11 Cr Q1) on ₹626.9 Cr revenue = 7% drag. DSCR 1.36x leaves little margin for rate shocks. De-leverage plan exists but not disclosed. At current leverage, FCF available for capex or buyback is constrained.

CBG policy flux (MDA subsidy, Sampoorna rollout)

Medium

CBG 40–50% PAT margins dependent on FOM monetization at ₹2,500–2,800/ton. MDA (fertilizer subsidy) under review; Sampoorna program coming with 'multiple corrections.' If subsidy cut, FOM realization falls, margin to 25–35% PBT. JV capex (₹760 Cr) is at risk if returns fall.

15 Cr liter court case unresolved

Medium

Not in base 44 Cr guidance. If it resolves, adds ~₹1,000 Cr incremental FY27 revenue and materially raises PAT. If it doesn't, upside story breaks. No timeline disclosed.

SAF adoption and pricing uncertainty

Medium

₹2,000 Cr capex for FY29 revenue is contingent on airline willingness to pay ₹180–200/liter (1.8x ATF). Carbon benefit alone may not drive adoption without mandates. EPC bidding in 2–3 months; execution risk high.

How the street is positioned

Post-result price action confirms the market believes the story, for now. The day-1 pop of +2.62% (from ₹419.15 pre-result) held—by day 5 the stock was up +4.19%. That tells you institutional buyers saw the dual-feed transition and CBG acceleration as credible, not a one-quarter fluke. Volume was normal, not climactic.

But valuation and positioning show cracks. The stock is at ₹481.6, -11.14% from its all-time high of ₹542. It's trading above its SMA20 (₹446.52), SMA50 (₹460.83), and SMA200 (₹433.48)—a classic uptrend. Yet RSI is 72.4 (overbought), and momentum could fade if Q2 earnings quality deteriorates.

Institutional flows are trimming, not adding. FII ownership fell 0.08 percentage points QoQ (0.58% now vs. 0.66% prior); DII fell 1.04pp (8.36% now vs. 9.40% prior). That's not a rout, but it's not conviction buying either. The June bulk deals show retail/prop activity (₹516–₹506/share range), but no promoter insider buying at these levels—a yellow flag.

The market's verdict is cautiously bullish on the decade-long structural story (ethanol blending, CBG policy tailwinds, SAF early-mover edge) but wary of the next quarter's earnings quality. That's a reasonable read.

The debate

What to watch next

Catalysts and decision points
  • 1 · Q2 FY27 sales and EBITDA margin (next quarter)

    Management guided 11–12 Cr liter sales. The acid test: does EBITDA margin hold above 20% without the inventory windfall, or does it compress to 16–18%? Maize cost trajectory (is it stabilizing or staying elevated at ₹25+/kg?) will answer this. If normalized, adjusted EBITDA margin validates the dual-feed thesis at ₹10–12/liter. If not, the bear case wins.

  • 2 · CBG JV first revenues (Q4 FY27, Sep–Dec 2026)

    3 Sumitomo plants + 6 GAIL plants (132 TPD total, 51% TruAlt ownership) expected to generate revenue by Q4. Key metrics: utilization (60% Y1 assumed), FOM realization (₹2,500–2,800/ton current, ₹6,000 target), gas pricing (₹84/kg static). If CBG PAT margin falls below 40% at 70%+ utilization, policy risk (MDA/Sampoorna) is real and de-rates capex returns.

  • 3 · Tender allocation fairness (Sept–Oct 2026, next bidding cycle)

    The new ethanol allocation cycle will tell you if 44 Cr liters was a low-ball due to 'unfair means' or a structural ceiling. If TruAlt secures 50+ Cr liters, the court case upside becomes less critical. If it stays at 44 Cr (or lower), tender allocation risk is embedded and FY27 revenue tops out ~₹3,000 Cr.

  • 4 · 15 Cr liter court case resolution (timing TBD)

    If implemented, adds ~₹1,000 Cr revenue upside (at ₹67/liter). PAT upside ₹100–150 Cr (at 12–15% margin). This is optionality, not base case. No timeline, so price it at <50% probability. Resolution or closure would materially de-risk the guidance and validate the bull case.

  • 5 · De-leverage plan disclosure

    MD dodged this on the call. Finance cost ₹44 Cr annualized is high relative to EBITDA ₹147 Cr (30% of EBITDA). If management commits to de-leverage (refinancing, asset sales, equity raise), it signals confidence in cash generation. Absence of a plan by Q2 call is a negative signal.

  • 6 · SAF capex progress (next 2–3 months, FEED completion)

    EPC bidding underway. Land procurement from Andhra Pradesh state. If execution slips (common on ₹2,000 Cr capex), FY29 revenue timeline at risk. Early wins (binding MOUs with airlines, finalized capex budget) would de-risk the story.

The verdict

Credibility grade: B. Management hit Q1 revenue and PAT targets disclosed in the CFO deck (₹625+ Cr, ₹59+ Cr). Guided 55 Cr liters ethanol capacity and CBG, SAF expansion timelines have not moved. Shortfall: 44 Cr liters orders (80% of capacity target) vs. 55 Cr full-year run-rate; 15 Cr liter court case remains unresolved with no formal timeline; Q1 QoQ PAT compression despite revenue growth signals margins softer than expected. Not a trust breach, but a reminder that the next two quarters are execution tests, not confirmation rallies.

TruAlt's dual-feed transition is real, and the economics (6% margin lift on grain vs. sugar) are proven. CBG capex and SAF ambitions are credible for a mid-sized biofuels player with government backing. But Q1's reported profit is inflated by an inventory benefit that fades in Q2. Tender allocation to 80% of capacity (44 Cr vs. 55 Cr liters) and unresolved court case add risk. The honest read is steady, disciplined capital deployment, not a breakout. Finance cost (₹44 Cr annualized) is material and unsustainable without de-leverage. The market's post-result rally (+4.19% by day 5) was justified but is now overbought (RSI 72.4). Conviction lies in Q2 earnings quality: if normalized maize cost (₹22–24/kg) and tender allocation dynamics hold firm, adjusted EBITDA margin (ex-inventory benefit) will stabilize around 18–20%, validating the dual-feed case. If not, downside to ₹420–440 is likely. The number to track is adjusted EBITDA margin per liter—it's the true measure of earnings power.

Informational and educational content only. Not investment advice.

Trualt Bioenergy Ltd (TRUALT) Q1 FY27 Results, Transcript & Analysis — StockWatch